Soombit.ai, a Seoul medical AI company that builds software to draft radiology reports, announced on 17 November 2026 that it had raised about ₩12bn (about $9.0m) in a Series A round.
SV Investment led the round. Altos Ventures, Kiwoom Investment and iM Investment Partners also took part, according to reports in Rapportian and Digital Today. The company did not disclose a valuation.
The company listed the round in its online newsroom on the same day and linked to Rapportian's article as its announcement. It has not published a separate press release of its own.
What Soombit.ai does
Soombit.ai's main product, AIRead-CXR, reads chest X-ray images and writes a draft of the preliminary report, which a radiologist then reviews. The company's website says the product holds a Class III approval from Korea's Ministry of Food and Drug Safety dated 1 April 2026, and that it is not cleared by the US Food and Drug Administration or sold in the United States.
Rapportian and Digital Today both reported that the approval was the first in Korea for a generative AI medical device that analyses images directly to produce a preliminary report. According to Rapportian, the model was trained on about 14 million images and reports, detects at least 57 findings and produces a draft in one to two seconds. Rapportian also reported that it works with hospitals' existing picture archiving systems without changes to their workflow.
The company's website cites six peer-reviewed papers, in Radiology, the American Journal of Roentgenology and European Radiology, and a reported 42% reduction in reading time. Neither news report gave customer names, hospital numbers, revenue or headcount.
Who is behind it
Soombit.ai was founded in July 2024. Its chief executive, Bae Woong, was previously chief healthcare officer at Kakao Brain, the AI research arm of Korean internet group Kakao. He started the company with colleagues from Kakao Brain who had worked on AI to assist with chest X-ray reading there, according to both reports.
Altos Ventures, which joined this round, was the company's first backer. Rapportian reported that Altos Ventures alone put ₩5bn (about $3.7m) into a seed round in 2024. Soombit.ai's newsroom lists the seed investment in November 2024 without giving an amount.
Alongside the Series A, the company was selected for the Scale-up TIPS programme of Korea's Ministry of SMEs and Startups, which provides up to ₩3bn (about $2.2m) in research and development funding over three years. That support is a government programme award, not equity. Rapportian put the company's total funding, including the seed round and the programme, at about ₩20bn (about $15m). Digital Today gave a figure of ₩15bn (about $11.2m), counting the Series A and the programme award.
What the money is for
Soombit.ai said it would use the money to extend its report-drafting technology from chest X-rays to CT and MRI scans, which involve three-dimensional images and several imaging sequences. It also plans to seek approvals in other markets, including from the FDA and under Europe's CE marking, and to start selling abroad.
Its next product, AIRead-CT, is designed to draft preliminary reports for brain, chest, and abdomen and pelvis CT scans. The company's website gives 2027 as the planned launch year. According to both reports, it will show the product for the first time at the RSNA 2026 radiology meeting in Chicago, which runs from 29 November to 2 December.
In comments reported by Rapportian and Digital Today, Bae said the company would build on the technology and experience gained from chest X-rays to move quickly into CT and MRI, with the aim of becoming essential infrastructure for radiologists around the world. He also said the company hoped to attract highly skilled staff to join the effort.
Company website: soombit.ai
